These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16237546)

  • 1. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
    Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
    Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
    Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
    Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
    Kirchheiner J; Ufer M; Walter EC; Kammerer B; Kahlich R; Meisel C; Schwab M; Gleiter CH; Rane A; Roots I; Brockmöller J
    Pharmacogenetics; 2004 Jan; 14(1):19-26. PubMed ID: 15128047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
    Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
    Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism.
    Kammerer B; Kahlich R; Ufer M; Laufer S; Gleiter CH
    Anal Biochem; 2005 Apr; 339(2):297-309. PubMed ID: 15797571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry.
    Kammerer B; Kahlich R; Ufer M; Laufer S; Gleiter CH
    Rapid Commun Mass Spectrom; 2004; 18(4):458-64. PubMed ID: 14966853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
    Kohl C; Steinkellner M
    Drug Metab Dispos; 2000 Feb; 28(2):161-8. PubMed ID: 10640513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
    Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
    Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry.
    Shaik AN; Grater R; Lulla M; Williams DA; Gan LL; Bohnert T; LeDuc BW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():164-173. PubMed ID: 26655108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
    Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
    Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine.
    de Vries JX; Völker U
    J Chromatogr; 1989 Aug; 493(1):149-56. PubMed ID: 2778004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
    Thijssen HH; Ritzen B
    Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.